Effects of chia seeds on acne

Effects of CHIA SEED based nutraceutical products on ACNE lesions plaques in a randomised trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN26733572

Enrollment

150

Registered

2017-03-14

Start date

2017-02-23

Completion date

Unknown

Last updated

2017-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne lesions Skin and Connective Tissue Diseases Acne lesions

Interventions

Participants are asked to fill out a food frequency questionnaire at the beginning of the study. Participants in all groups eat a placebo daily for one month. Participants are then randomly allocated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women between 18-65 years of age 2. Caucasian 3. Chronic acne lesions of any severity (treated and untreated)

Exclusion criteria

Exclusion criteria: 1. Smoking 2. Obesity (BMI >30 kg/m2) 3. Diabetes 4. Hepatic disease 5. Renal disease 6. Heart disease 7. Family history of chronic diseases 8. Heavy physical exercise (>10 h/week) 9. Pregnant women, women suspected of being pregnant, women who hoped to become pregnant, breastfeeding 10. Birch pollen allergy 11. Use of vitamin/mineral supplements 2 weeks prior to entry into the study 12. Donation of blood less than 3 months before the study

Design outcomes

Primary

Measure	Time frame
Severity of acne lesions are measured using the Global Acne Grading System (GAGS) score at baseline and 16 weeks.	—

Secondary

Measure	Time frame
1. Clinical history is measured both by interviews and previous clinical data at baseline 2. Itchiness is measured using Visual Analogue Scale (VAS) at baseline, 4, 8, 12, and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12, and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12, and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff baseline, 4, 8, 12, and 16 weeks 6. Blood analysis (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) is measured using a blood test (analysis by a spectrophotometer) at baseline, 4, 8, 12, and 16 weeks	—

Measure

Time frame

1. Clinical history is measured both by interviews and previous clinical data at baseline 2. Itchiness is measured using Visual Analogue Scale (VAS) at baseline, 4, 8, 12, and 16 weeks 3. Nutrient intake and dietary habits are measured using a seven day food record validated nutritional questionnaire at baseline, 4, 8, 12, and 16 weeks 4. Blood pressure is measured using a blood pressure cuff at baseline, 4, 8, 12, and 16 weeks 5. 24 hour ambulatory blood pressure is measured using blood pressure cuff baseline, 4, 8, 12, and 16 weeks 6. Blood analysis (AST, ALT, ?-GTP, ALP, LDH, Albumin, Total bilirubin, Creatinine) is measured using a blood test (analysis by a spectrophotometer) at baseline, 4, 8, 12, and 16 weeks

—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026